TScan Therapeutics (NASDAQ:TCRX) Lowered to “Hold” Rating by Lifesci Capital

Posted by Geri Gentry on Sep 4th, 2026

Lifesci Capital lowered shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) from a strong-buy rating to a hold rating in a research report report published on Wednesday morning,Zacks reports.

A number of other research firms have also issued reports on TCRX. Wedbush lowered TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of TScan Therapeutics in a report on Tuesday, June 23rd. Benchmark restated a “buy” rating on shares of TScan Therapeutics in a research report on Thursday, August 13th. HC Wainwright reiterated a “buy” rating on shares of TScan Therapeutics in a research report on Wednesday, August 12th. Finally, Wall Street Zen lowered shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, TScan Therapeutics has an average rating of “Hold” and a consensus price target of $4.67.

Get Our Latest Analysis on TCRX

TScan Therapeutics Stock Performance

TCRX opened at $0.37 on Wednesday. The stock has a market cap of $25.14 million, a P/E ratio of -0.41 and a beta of 1.07. TScan Therapeutics has a 1-year low of $0.35 and a 1-year high of $2.57. The stock’s 50 day simple moving average is $0.84 and its 200 day simple moving average is $0.98. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.37 and a quick ratio of 3.37.

TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. The company had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.88 million. As a group, equities analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors have recently bought and sold shares of TCRX. Boothbay Fund Management LLC increased its position in TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after buying an additional 9,676 shares during the period. Bank of America Corp DE grew its stake in shares of TScan Therapeutics by 48.7% during the 1st quarter. Bank of America Corp DE now owns 57,529 shares of the company’s stock valued at $58,000 after buying an additional 18,829 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of TScan Therapeutics by 8.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company’s stock worth $417,000 after buying an additional 22,642 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new stake in shares of TScan Therapeutics during the 4th quarter worth $25,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

(Get Free Report)

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.